Hypothesis

Aging‑related increase in perineuronal net (PNN) density raises the local concentration of heparan sulfate proteoglycans, which lowers the liquid‑liquid phase separation (LLPS) threshold for tau and promotes its transition to a solid‑like state, thereby converting physiological over‑consolidation into pathological aggregation.

Mechanistic Rationale

1. PNN composition and tau interaction – PNNs are enriched in chondroitin sulfate proteoglycans and heparan sulfate moieties that bind tau with high affinity [2][3]. This binding concentrates tau within the extracellular matrix, effectively raising its local concentration above the critical concentration for LLPS.
2. ECM stiffness and phase behavior – Increased PNN deposition correlates with heightened tissue stiffness [4]. Stiff matrices restrict tau diffusion, prolonging residence time in condensation zones and favoring nucleation of solid aggregates.
3. Disease mutations shift thresholds – Familial tau mutations reduce the concentration needed for LLPS and solidification [7]. In an aged brain, the combined effect of elevated baseline tau concentration (due to reduced clearance) and PNN‑mediated local enrichment pushes mutant and wild‑type tau past the percolation threshold, driving pathological solidification.
4. Contrast with Alzheimer’s tissue softening – Global softening observed in AD may result from extensive tau‑driven solidification that disrupts cytoskeletal integrity and extracellular crosslinking, leading to a net loss of tensile strength despite local ECM remodeling [5].

Testable Predictions

• Prediction 1: Enzymatic degradation of PNNs (e.g., chondroitinase ABC treatment) in aged mice will increase tau solubility and reduce insoluble tau aggregates without altering total tau expression.
• Prediction 2: Local infusion of heparan sulfate mimetic peptides will exacerbate tau LLPS in hippocampal slices, increasing Thioflavin‑S positive puncta, an effect blocked by excess soluble heparin.
• Prediction 3: Atomic force microscopy measurements will show that regions with higher PNN density exhibit greater elastic modulus and concomitantly higher propensity for tau‑induced solidification in vitro.
• Prediction 4: Behavioral assays (e.g., reversal learning) will improve following PNN reduction in aged tau transgenic mice, correlating with decreased tau aggregation.

Experimental Approach

1. Animal models: Use 18‑month‑old wild‑type and P301S tau transgenic mice. Treat one cohort with intracereventricular chondroitinase ABC; control receives vehicle.
2. Biochemical assays: Fractionate brain extracts into soluble and insoluble fractions; quantify tau by ELISA and western blot.
3. Imaging: Perform immunofluorescence for PNNs (WFA staining) and tau aggregates (AT8, Thioflavin‑S). Correlate PNN intensity with tau pathology across regions.
4. Mechanics: Conduct atomic force microscopy on fresh slices to map elastic modulus; overlay with tau aggregation maps.
5. Behavior: Assess cognitive flexibility using a water‑maze reversal learning task.
6. Controls: Verify that chondroitinase does not affect tau expression levels or neuronal viability (NeuN, LDH release).

Falsifiability

If PNN degradation fails to alter tau solubility, aggregation, or mechanics, or if heparan sulfate enrichment does not increase LLPS propensity, the hypothesis that PNNs drive tau solidification via LLPS threshold modulation would be refuted. Conversely, supportive data would validate the mechanistic link between ECM consolidation, phase‑transition biophysics, and cognitive aging.